US20150141501A1 - Ultrapure tetrahydrocannabinol-11-oic acids - Google Patents

Ultrapure tetrahydrocannabinol-11-oic acids Download PDF

Info

Publication number
US20150141501A1
US20150141501A1 US14/546,116 US201414546116A US2015141501A1 US 20150141501 A1 US20150141501 A1 US 20150141501A1 US 201414546116 A US201414546116 A US 201414546116A US 2015141501 A1 US2015141501 A1 US 2015141501A1
Authority
US
United States
Prior art keywords
ajulemic acid
receptor
affinity
acid
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/546,116
Other languages
English (en)
Inventor
Mark Tepper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/546,116 priority Critical patent/US20150141501A1/en
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Assigned to Corbus Pharmaceutics Inc. reassignment Corbus Pharmaceutics Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEPPER, MARK
Publication of US20150141501A1 publication Critical patent/US20150141501A1/en
Priority to US15/220,127 priority patent/US10085964B2/en
Priority to US15/347,059 priority patent/US9801849B2/en
Priority to US15/347,104 priority patent/US9820964B2/en
Assigned to CORBUS PHARMACEUTICALS, INC. reassignment CORBUS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEPPER, MARK
Assigned to CORBUS PHARMACEUTICALS, INC. reassignment CORBUS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEPPER, MARK
Assigned to CORBUS PHARMACEUTICALS, INC. reassignment CORBUS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEPPER, MARK
Priority to US15/698,544 priority patent/US10154986B2/en
Priority to US16/198,381 priority patent/US10369131B2/en
Priority to US16/425,196 priority patent/US11052066B2/en
Priority to US17/336,759 priority patent/US20220117931A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention is in the field of medicinal chemistry and relates to ultrapure tetrahydrocannabinol-11-oic acids compounds, pharmaceutical compositions and synthesis thereof.
  • the invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat and/or prevent various conditions such as inflammation, pain and fibrosis.
  • Tetrahydrocannabinol is the major psychoactive constituent of marijuana.
  • THC has been reported to exhibit other activities, some of which may have therapeutic value, including analgesic, anti-inflammatory and anti-emetic properties.
  • the potential therapeutic value of THC has led to a search for related compounds which minimize the psychoactive effects, while retaining the activities of potential medicinal value.
  • (6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydro-cannabinol-9-carboxylic acid (IUPAC name), also known as ajulemic acid (AJA) is a candidate for the treatment of pain and inflammation either alone or in combination with other agents.
  • cannabinoid receptors CB1 and CB2 play an important role in the initiation and maintenance of post-synaptic signaling and immune mechanisms related to nociception, sensitization, pain signal transmission and pain processing.
  • impure preparations of ajulemic acid have been shown to have affinity for both CB1 and CB2 receptors, with more affinity for the CB1 receptor (14).
  • the present invention provides a highly purified form of ajulemic acid which exhibits a higher affinity for the CB2 receptor than the CB1 receptor.
  • the ultrapure ajulemic acid can be used to treat fibrotic diseases such as scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, fibrosis of organs such as liver, esophagus, heart, lung, intestines, etc., and other scarring/wound healing abnormalities, post-operative adhesions, and reactive fibrosis as well as, inflammatory diseases such as lupus, multiple sclerosis, rheumatoid arthritis, dermatomyositis, Marfan's syndrome, psoriasis, Type 1 diabetes, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Parkinson's disease, Alzheimer's
  • the present invention provides for a composition comprising ultrapure ajulemic acid, wherein the ajulemic acid has an affinity for the CB2 receptor greater than its affinity for the CB1 receptor.
  • ultrapure ajulemic acid has an affinity for the CB2 receptor ranging from about 2 times to about 100 times, from about 5 times to 50 times, from about 15 times to 50 times, from about 10 times to about 40 times, or from about 20 times to about 40 times greater than its affinity for the CB1 receptor.
  • the present invention provides for a composition comprising ajulemic acid, wherein the ajulemic acid has a K i for the CB1 receptor greater than its K i for the CB2 receptor.
  • ajulemic acid has a K i for the CB1 receptor ranging from about 2 times to about 100 times, from about 5 times to 50 times, from about 15 times to 50 times, from about 10 times to about 40 times, or from about 20 times to about 40 times greater than its K i for the CB2 receptor.
  • the ajulemic acid in the present composition may have purity greater than about 97%, greater than about 98%, or greater than about 99%.
  • the present invention also provides for a composition comprising ajulemic acid, wherein the ajulemic acid has a purity greater than about 97%, greater than about 98%, or greater than about 99%.
  • the present invention provides for a composition comprising ajulemic acid, wherein the ajulemic acid has less than about 1% (w/w), less than about 0.5% (w/w), less than about 0.3% (w/w), less than about 0.2% (w/w), less than about 0.1% (w/w), or less than about 0.05% (w/w) of 11-hydroxy-(6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydrocannabinol (HU-210) or other highly CB1 active compounds.
  • the ajulemic acid in the present composition may have an affinity for the CB2 receptor greater than its affinity for the CB1 receptor.
  • ajulemic acid has an affinity for the CB2 receptor ranging from about five times to fifty times, from about ten times to fifty times, from about twenty times to about forty times greater than its affinity for the CB1 receptor.
  • the present invention further provides for a method of treating a subject with fibrotic disease comprising administering a therapeutically effective amount of ajulemic acid to the subject, wherein the ajulemic acid has an affinity for the CB2 receptor greater than its affinity for the CB1 receptor.
  • ajulemic acid has an affinity for the CB2 receptor ranging from about 2 times to about 100 times, from about 5 times to 50 times, from about 15 times to 50 times, from about 10 times to about 40 times, or from about 20 times to about 40 times greater than its affinity for the CB1 receptor.
  • the fibrotic disease may be dermal fibrosis, lung fibrosis, liver fibrosis, kidney fibrosis, heart fibrosis or any other organ fibrosis.
  • the fibrotic disease may be scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, cystic fibrosis, chronic kidney disease, chronic graft rejection, or other scarring/wound healing abnormalities, post-operative adhesions, and reactive fibrosis.
  • the ajulemic acid may be administered orally, intravenously, topically, ophthalmically, interstitially, by inhalation or via an implant or patch.
  • the present invention provides for a method of reducing pain in a subject comprising, administering a therapeutically effective amount of ultrapure ajulemic acid.
  • the ajulemic acid may have an affinity for the CB2 receptor greater than the affinity for the CB1 receptor.
  • ajulemic acid has an affinity for the CB2 receptor ranging from about 2 times to about 100 times, from about 5 times to 50 times, from about 15 times to 50 times, from about 10 times to about 40 times, or from about 20 times to about 40 times greater than its affinity for the CB1 receptor.
  • the reduction of pain may be measured along at least one pain scale.
  • the pain may be reduced by at least about 1 point, at least about 2 points, at least about 3 points, at least about 4 points, at least about 5 points, at least about 6 points, at least about 7 points, or at least about 8 points on an 11-point pain scale.
  • the present invention also provides for a method of reducing inflammation in a subject comprising, administering a therapeutically effective amount of ultrapure ajulemic acid.
  • the ajulemic acid may have an affinity for the CB2 receptor greater than the affinity for the CB1 receptor.
  • ajulemic acid has an affinity for the CB2 receptor ranging from about 2 times to about 100 times, from about 5 times to 50 times, from about 15 times to 50 times, from about 10 times to about 40 times, or from about 20 times to about 40 times greater than its affinity for the CB1 receptor.
  • the reduction of inflammation may be measured by at least one inflammation assay.
  • FIG. 1 shows the structure of ajulemic acid ((6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydrocannabinol-9-carboxylic acid) and the naturally occurring pentyl side chain analog, (6aR,10aR)- ⁇ 8-tetrahydrocannabinol-9-carboxylic acid.
  • FIG. 2 shows some critical steps for the synthesis of ultrapure ajulemic acid synthesis.
  • FIG. 3 shows a scheme for synthesis of ultrapure Ajulemic Acid (AJA).
  • FIG. 4 shows a comparison of the properties of batches of AJA as described in U.S. Pat. No. 5,338,753 and ultrapure AJA made with 5-(1′,1′-dimethylheptyl)-resorcinol (DMHR)—lot JBA1001A04.
  • DMHR 5-(1′,1′-dimethylheptyl)-resorcinol
  • FIGS. 5A and 5B show an LC-MS analysis of AJA made with ultrapure 5-(1′,1′-dimethylheptyl)-resorcinol (DMHR).
  • DMHR ultrapure 5-(1′,1′-dimethylheptyl)-resorcinol
  • FIG. 6 shows an HPLC analysis of synthesized ultrapure AJA.
  • FIG. 7 shows a magnified image of an HPLC analysis of synthesized ultrapure AJA.
  • FIG. 8 shows an analysis of ultrapure AJA showing 99.8% purity.
  • FIG. 9 shows affinity constants for selected cannabinoids.
  • the ultrapure AJA shows a major difference between the K i for CB1 and CB2 receptors.
  • FIG. 10 shows the cataleptic and antinociceptive effects of AJA from Burstein, S. H. et al. (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities, J Med Chem 35(17), 3135-3141.
  • FIG. 11 shows plasma and brain levels of cannabinoids following systemic administration in rats as described in Dyson et al. [3].
  • FIG. 12 shows representative binding curves of selected cannabinoids for CB2 and CB1.
  • FIG. 13 demonstrates effects of CP55940 (circles) and JBT-101 (ultrapure AJA; squares) on [35S]GTP ⁇ S turnover in hCB1 and hCB2 receptors (upper and lower panels, respectively) expressed in HEK-293 cells.
  • Each concentration-effect curve represents the mean ( ⁇ SEM) of 4 repetitions. Conditions used were adapted from Wiley et al. (20).
  • FIG. 14 shows that JBT-101 is active in the ring test only at high doses of 30 mg/kg and above. All drugs were given orally in oil. Conditions as reported by Wiley J L and Martin B R (21). This effect is considered to be CB1 mediated.
  • FIG. 15 shows that JBT-101 is active in the mouse hot plate assay only at high doses of 30 mg/kg and above.
  • HU-239 i.e., AJA reported in U.S. Pat. No. 5,338,753
  • MPE maximum possible effect.
  • FIG. 16 shows that JBT-101 is inactive in the mouse hypothermia assay. All drugs were given orally in oil. Experimental conditions as reported by Wiley J L and Martin B R (21). This effect is considered to be CB1-mediated.
  • FIG. 17 shows the CB2 specificity of ultrapure JBT-101 in stimulation of PGJ in HL-60 cells.
  • the CB2 antagonist SR144528 reduced ultrapure AJA-induced PGJ synthesis in HL60 immune system cells at low concentrations (squares).
  • the CB1 antagonist SR141716 has a much smaller effect (triangles).
  • DMSO control open circles).
  • FIG. 18 shows that JBT-101 is effective at inhibiting skin fibrosis in the bleomycin mouse model of scleroderma, a CB2 dependent response.
  • Mice were treated daily with local injection of bleomycin and administered orally the indicated doses of JBT-101 (ultrapure AJA). All doses, including a dose of 1 mg/kg (data not shown) were equally effective at inhibiting skin thickening.
  • FIG. 19 shows that JBT-101 (ultrapure AJA) is effective at doses well below the doses in which CB1 activity is observed, at inhibiting paw volume in a model of arachidonic acid induced paw edema, a CB2 dependent response.
  • Mice were administered orally the indicated doses of JBT-101 (ultrapure AJA) followed 90 minuted later with intraplanar injection of arachidonic acid in the right paw. Right paw volume was measured 45 minutes post-arachidonic acid injection.
  • Tetrahydrocannabinol is the major psychoactive constituent of marijuana.
  • THC has been reported to exhibit other activities, some of which may have therapeutic value, including analgesic, anti-inflammatory and anti-emetic properties.
  • the potential therapeutic value of THC has led to a search for related compounds which minimize the psychoactive effects, while retaining the activities of potential medicinal value.
  • (6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydro-cannabinol-9-carboxylic acid also known as ajulemic acid
  • CB1 and CB2 receptors play an important role in the initiation and maintenance of post-synaptic signaling and immune mechanisms related to nociception, sensitization, pain signal transmission and pain processing.
  • C. Voscopoulos and M. Lema Br. J. Anaesth. (2010) 105 (suppl 1): i69-i85.
  • Previously, earlier preparations of ajulemic acid have been shown to have affinity for both CB1 and CB2 receptors, with higher affinity for the CB1 receptor.
  • the present invention for the first time, provides for a purified form of ajulemic acid with higher affinity for the CB2 receptor than the CB1 receptor.
  • the purified form of ajulemic acid is also referred to as ultrapure ajulemic acid.
  • the degree of purity of the ajulemic acid is greater than about 95% (w/w), greater than about 96% (w/w), greater than about 97% (w/w), greater than about 98% (w/w), greater than about 99% v, greater than about 99.1% (w/w), greater than about 99.2% (w/w), greater than about 99.3% (w/w), greater than about 99.4% (w/w), greater than about 99.5% (w/w) or greater than about 99.9% (w/w).
  • the degree of purity may be assessed by a variety of different methods as described further below.
  • the affinity of the purified form of ajulemic acid for the CB2 receptor can range from about five-fold to about ten-fold greater than the affinity for the CB1 receptor, but affinity ranges from about 5 ⁇ -50 ⁇ , 7 ⁇ -10 ⁇ , 8 ⁇ -15 ⁇ , 10 ⁇ -20 ⁇ , 15 ⁇ -30 ⁇ , 25 ⁇ -50 ⁇ , 40-75 ⁇ and 50 ⁇ -100 ⁇ are also encompassed by the invention (ranges represent ratios of affinity of ajulemic acid for the CB2 receptor versus the CB1 receptor).
  • the present compound has the structure shown in Formula I.
  • the present compounds may have a purity of greater than about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5% or about 99.9%.
  • the present compounds may contain less than 0.1% (w/w) of 11-hydroxy-(6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydrocannabinol (HU-210) or other highly CB1 active compounds.
  • the purified form of the present compounds may also be referred to as an ultrapure form.
  • the pharmaceutically acceptable salts, esters, or solvate of the compound in Formula I are also encompassed.
  • R 1 is hydrogen, COCH 3 or COCH 2 CH 3 ;
  • R 2 is a branched C5-C12 alkyl group which may optionally have a terminal aromatic ring, or optionally a branched OCHCH 3 (CH 2 ) m alkyl group which may have a terminal aromatic ring and where m is 0 to 7;
  • R 3 is hydrogen, a C1-8 alkyl or a C1-8 alkanol group; and
  • Y is either zero, i.e. absent, or a bridging group of NH or oxygen, (provided that where Y is oxygen and R 2 is a branched C5-C, 12 alkyl, R 3 is not CHCH 3 ).
  • the present invention provides for a process of preparing a purified form of ajulemic acid.
  • the process may contain the following steps: (a) reacting Para-mentha-2,8-dienl-ol (PMD) and 5-(1,1-dimethylheptyl) resorcinol (DMHR) to form (6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydrocannabinol (Compound 8); (b) acetylating Compound 8 to form (6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydrocannabinol acetate (Compound 9); (c) oxidizing Compound 9 to form 11-oxo-(6aR,10aR)-3-(1′,1′-dimethylheptyl)- ⁇ 8-tetrahydrocannabinol acetate (Compound 10); (d
  • the molar ratio of hydrogen peroxide to Compound 9 may also range from about 2:1 to about 6:1, from about 2:1 to about 5:1, from about 2:1 to about 4:1, about 2:1, about 2.5:1, about 3:1, about 3.5:1, or about 4:1.
  • the molar ratio of PMD to DMHR may range from about 1:1 to about 3:1, from about 1:1 to about 2:1, from about 1:1 to about 1.1:1, about 1.1:1, or about 1.2:1.
  • Step (a) may be carried out at about 50° C. to about 120° C., about 60° C. to about 110° C., about 70° C. to about 100° C., about 75° C. to about 90° C., about 70° C.
  • the purified ajulemic acid may have a purity greater than about 95% (w/w), greater than about 96% (w/w), greater than about 97% (w/w), greater than about 98% (w/w), greater than about 99% v, greater than about 99.1% (w/w), greater than about 99.2% (w/w), greater than about 99.3% (w/w), greater than about 99.4% (w/w), greater than about 99.5% (w/w) or greater than about 99.9% (w/w).
  • the compounds of the invention contain one or more chiral centers.
  • the term “purity” can also encompass chiral purity.
  • the purity of a stereoisomer of ajulemic acid refers to chemical purity and/or chiral purity of the stereoisomer.
  • the purity of ajulemic acid can include both the chemical purity and the chiral purity of ajulemic acid.
  • the chiral purity of a stereoisomer of ajulemic acid may be greater than about 98.5% (w/w), greater than about greater than about 95% (w/w), greater than about 96% (w/w), greater than about 97% (w/w), greater than about 98% (w/w), greater than about 99% v, greater than about 99.1% (w/w), greater than about 99.2% (w/w), greater than about 99.3% (w/w), greater than about 99.4% (w/w), greater than about 99.5% (w/w) or greater than about 99.9% (w/w).
  • the purity of the present compounds may be assayed by gas chromatography (GC) or high pressure liquid chromatography (HPLC).
  • Other techniques for assaying the purity of ajulemic acid and for determining the presence of impurities include, but are not limited to, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), GC-MS, infrared spectroscopy (IR), thin layer chromatography (TLC), and differential scanning calorimetry. Chiral purity can be assessed by chiral GC or measurement of optical rotation.
  • the purified form of ajulemic acid may be stable after storage.
  • the present composition may contain greater than about 98.5% (w/w), greater than about 99% (w/w), greater than about 99.5% (w/w), or greater than about 99.9% (w/w) ajulemic acid.
  • the present composition can contain greater than about 98.5% (w/w), greater than about 99% (w/w), greater than about 99.5% (w/w), or greater than about 99.9% (w/w) ajulemic acid.
  • Ultrapure DMHR (5-(1,1-dimethylheptyl)resorcinol) may be purchased from Norac Pharma (Azusa, Calif.).
  • the amount of PMD (7a in FIG. 3 ) used in the reaction was reduced from 1.25 equivalents to 1.1 equivalents, because the 0.1 equivalents excess of PMD was sufficient to react with all of the DMHR (6 in FIG. 3 ).
  • Toluene was previously used as an extraction solvent after the hydrogen peroxide oxidation. The procedure then required evaporating the mixture to dryness and adding heptane. Since evaporation to dryness is not easily scalable and a solvent swap from toluene to heptane is not efficiently feasible, other solvents were evaluated as possible extraction solvents. Firstly, heptane was assessed. Although heptane successfully extracted the product into the organic layer, the phase split was slow and there were three layers. On the second attempt, no extraction solvent was used and it was observed that quenching the hydrogen peroxide reaction with 20 wt % sodium thiosulfate led to two phases. Thus, the aqueous layer could be removed without additional organic solvents.
  • HPLC analysis showed that the top organic layer contained impurities and no product while the two bottom layers contained mostly product with trace impurities. Although the phase split was still hard to visualize due to the dark color, the heptane extraction was able to separate the product from the impurities.
  • the next step was to filter the batch through Celite to break up emulsions. Because the filtration was noticeably slow, the aqueous layer was removed prior to filtration. The solvent swap from MTBE to acetonitrile was successful and seed crystals were no longer required for crystallization because the Crude Ajulemic acid consistently crystallizes following the procedure described.
  • Step 4 The main issue with Step 4 was the drying time. It required 9 days to reach the specification of ⁇ 410 ppm acetonitrile for the previous 400 g non-GMP campaign batch. Thus, crystallization from IPA/water was evaluated. A solubility study showed that Ajulemic acid in a 1:1 IPA/water mixture had a similar solubility to Ajulemic acid in a 3:1 acetonitrile/water mixture. Although Ajulemic acid was successfully isolated from IPA/water, the drying time did not improve, requiring >7 days to reach the specification of ⁇ 5000 ppm IPA on a 2.5 g scale. The amount of IPA remaining in the product did not correlate with the LOD, suggesting that water played a key role in drying time. Therefore, crystallization from pure acetonitrile was evaluated on a 19.5 g scale. This produced a much shorter drying time with no detectable amount of acetonitrile at 81 h.
  • a use-test of ultrapure DMHR (purity of 99.4% (AUC)) was successfully taken through to Ajulemic Acid.
  • the purity of the Ajulemic acid was 99.9% (AUC) with no single peak ⁇ 0.04%.
  • the reaction was determined complete after 2 h by HPLC, detecting no cannabidiol and obtaining a ⁇ 8: ⁇ 9 ratio of 106:1 (specification was ⁇ 2.0% (AUC) cannabidiol and ⁇ 8: ⁇ 9 ratio >4:1).
  • the batch was held overnight at 25° C. and atmospheric pressure.
  • the batch was reheated to 70-80° C., and pyridine (10.70 kg, 1.6 equiv.) and acetic anhydride (13.80 kg, 1.6 equiv.) were each added over ⁇ 30 min while maintaining the batch temperature at 70-80° C. After 2 h the batch was sampled and passed the specification of ⁇ 2.0% (AUC) of Compound 1 with 0.4% (AUC) Compound 1 detected. Water (160.0 kg, 8 equiv.) was added and the batch was adjusted to 50-60° C. The lower aqueous layer was removed and the batch was further washed with water (40 kg, 2.0 equiv.) at 50-60° C. The reaction mixture was transferred from the 200-gallon reactor to the 250-liter reactor.
  • the batch was held at 20-30° C. overnight.
  • IPA 31.4 kg, 2 vol. equiv.
  • the batch was reheated to 45-55° C., water (40.0 kg, 2 vol. equiv.) was added, and the temperature was maintained for an additional ⁇ 1 h before cooling to 25 ⁇ 2° C. at ⁇ 10° C./hour.
  • the batch was held at this temperature for over 16 h then cooled to 0-5° C.
  • the product was offloaded and gave a total actual weight of 25.76 kg of Compound 2—The 1st crop yielded an actual weight of 14.50 kg (97.0% (AUC) purity) and the 2nd crop yielded an actual weight of 11.26 kg (93.3% (AUC) purity).
  • the batch temperature was then adjusted to 10-25° C. and held at this temperature until the reaction met the specifications of ⁇ 10.0% (AUC) of Compound 10 by HPLC.
  • AUC ⁇ 10.0%
  • the reaction was deemed complete (1.7% (AUC) residual Compound 10) and was slowly quenched with 20 wt % sodium thiosulfate solution (98.8 kg, 2 equiv.) while maintaining the batch temperature ⁇ 35° C. After 2 h 13 min, there was no trace of peroxide.
  • the batch was filtered through a pad of Celite and the Celite cake was washed with 22.9 kg THF (1 vol. equiv.). The phases were allowed to separate and the aqueous layer was drained.
  • reaction mixture was then washed with 10 wt % sodium chloride (51.6 kg, 2 equiv.) and transferred back into the cleaned 200-gallon reactor along with water (128.8 kg, 5 equiv.).
  • 50 wt % sodium hydroxide solution (18.8 kg, 3.8 equiv.) while maintaining the batch temperature ⁇ 55° C.
  • the batch was held at 45-55° C. for ⁇ 1 h after which time it was sampled and met the specification of ⁇ 2.0% (AUC) of Compound 11 by HPLC, detecting 0.1% (AUC) residual Compound 11.
  • the reaction was allowed to cool to 25 ⁇ 2° C. and heptane (44.1 kg, 2.5 vol. equiv.) was added. The reaction mixture was stirred for 30 min and settled for 48 min. Three phases were observed: bottom red/brown aqueous layer, middle viscous black layer, and top clear red organic layer. The top organic layer was removed and the middle and bottom product containing layers were combined and washed with another 44.1 kg (2.5 vol. equiv.) of heptane. Once again, three phases were observed and the top organic layer was removed.
  • the organic layer was washed once more with water (7.40 kg, 1.4 equiv.) to obtain pH 4 which passed the specification of pH >3.
  • the batch was allowed to cool to 0-5° C. at ⁇ 10° C./h overnight, followed by holding for 3 h at 0-5° C.
  • the batch was filtered, washed with pre-cooled heptane (11.2 kg, 3 equiv.), and dried under vacuum at 122° F. (50 ⁇ 5° C.).
  • the product was offloaded and gave Acetylated Ajulemic Acid (5.03 kg actual weight, 86.1% yield) as a white solid with a purity of 99.2% (AUC) by HPLC (Method A).
  • the organic layer was filtered through Celite, a 10-micron filter, and a 2.4 micron filter into a 250-liter reactor.
  • the 40-liter reactor was then washed with MTBE (1.86 kg, 0.5 vol. equiv.) and the batch along with the wash was transferred back into the cleaned 40-liter reactor through a 10-micron and a 2.4 micron filter.
  • MTBE (10 L, 2 vol. equiv.) was distilled off and acetonitrile (17.4 kg, 4.4 vol. equiv.) was added. Then, 22.25 L ( ⁇ 4.4 vol. equiv.) of solvent was distilled off, and the distillate was analyzed by NMR to reveal 46% MTBE.
  • Affinity is a measure of the strength of the binding interaction between two or more distinct molecular entities (e.g. between a compound and a receptor) that can be defined by equilibrium binding constants or kinetic binding rate parameters.
  • suitable constants or parameters and their measurement units include, but are not limited to, association constant (K A ); dissociation constant (K D ) or inhibition constant (KO; association rate constant (K on ) and dissociation rate constant (K off ).
  • K i equals [receptor] ⁇ [inhibitor]/[receptor bound by inhibitor], so K i is an equilibrium constant for the inhibitor binding to the receptor.
  • K A higher values mean stronger or greater binding affinity.
  • K i (or K D ) lower values mean a stronger or greater binding affinity.
  • the present compounds have a greater affinity for the CB2 receptor than for the CB1 receptor. This means that the present compounds (e.g., the ultrapure AJA) bind more tightly to CB2 than CB1, i.e., with a smaller K i (CB2) (i.e., K i for the CB2 receptor) than its K i (CB1) (i.e., K i for the CB1 receptor). Likewise, the present compounds (e.g., the ultrapure AJA) have a lesser affinity for the CB1 receptor than for the CB2 receptor. In other words, the present compounds (e.g., the ultrapure AJA) bind less strongly to CB1 than CB2, i.e., with a larger K i (CB1) than its K i (CB2).
  • the affinity of the purified form of ajulemic acid for the CB2 receptor can range from about 5 to about 10-fold greater than the affinity for the CB1 receptor. Ranges from about, 5 ⁇ -about 50 ⁇ , about 7 ⁇ -about 10 ⁇ , about 8 ⁇ -about 15 ⁇ , about 10 ⁇ -about 20 ⁇ , about 15 ⁇ -about 30 ⁇ , about 25 ⁇ -about 50 ⁇ , about 40-about 75 ⁇ , about 50 ⁇ -about 100 ⁇ , about 2 ⁇ -about 1000 ⁇ , about 2 ⁇ -about 800 ⁇ , about 5 ⁇ -about 600 ⁇ , about 10 ⁇ -about 500 ⁇ , about 15 ⁇ -about 300 ⁇ , about 5 ⁇ -about 200 ⁇ , about 10 ⁇ -about 100 ⁇ , about 20 ⁇ -about 80 ⁇ , or about 10 ⁇ -about 50 ⁇ are also encompassed by the invention (ranges represent ratios of affinity of ajulemic acid for CB2 receptor vs. affinity for CB1 receptor, e.g., K i (CB1)/K i (CB2).
  • the K i (CB1) i.e., K i for the CB1 receptor
  • the K i (CB1) may be at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 8-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 200-fold, at least about 400-fold, at least about 500-fold, at least about 1000-fold, at least about 10,000-fold, from about 2-fold to about 10,000-fold, from about 2-fold to about 1,000-fold, from about 5-fold to about 500-fold, from about 5-fold to about 100-fold, from about 7-fold to about 10-fold, from about 8-fold to about 15-fold, from about 10-fold to about 20-fold, from about 15-fold to about 30-fold, from about 25-fold to about 50-fold, from about 40-fold to about 75-fold, or from about 50-fold to about 100-fold, of the K i (CB1) (i.e., K i
  • the ratio of K i (CB1)/K i (CB2) of the present compounds may be at least about 2, at least about 3, at least about 4, at least about 5, at least about 8, at least about 10, at least about 50, at least about 100, at least about 200, at least about 400, at least about 500, at least about 1000, at least about 10,000, from about 2 to about 10,000, from about 2 to about 1,000, from about 5 to about 500, from about 5 to about 100, from about 7 to about 10, from about 8 to about 15, from about 10 to about 20, from about 15 to about 30, from about 25 to about 50, from about 40 to about 75, or from about 50 to about 100.
  • the purified form of AJA has a K i for the CB2 receptor of about 150 nM or less, about 125 nM or less, about 110 nM or less, about 100 nM or less, about 90 nM or less, about 80 nM or less, about 70 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, or about 30 nM or less.
  • Any conventional method for measuring receptor binding affinity can be used to assay binding of the ligand to the CB1 or CB2 receptor (see, Pertwee RG. Pharmacological action of cannabinoids. Handbook Exp. Pharmacol 168:1-51 (2005); McPartland et al. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British J. Pharmacology 152:583-593 (2007)).
  • Binding affinity between two components may be measured directly or indirectly. Indirect measurement of affinity may be performed using surrogate properties that are indicative of, and/or proportional to, affinity.
  • surrogate properties include: the quantity or level of binding of a first component to a second component, or a biophysical characteristic of the first component or the second component that is predictive of or correlated to the apparent binding affinity of the first component for the second component. Specific examples include measuring the quantity or level of binding of first component to a second component at a sub-saturating concentration of either the first or the second component.
  • Other biophysical characteristics that can be measured include, but are not limited to, the net molecular charge, rotational activity, diffusion rate, melting temperature, electrostatic steering, or conformation of one or both of the first and second components.
  • Yet other biophysical characteristics that can be measured include determining stability of a binding interaction to the impact of varying temperature, pH, or ionic strength.
  • Binding affinities can be quantified by measuring the rates of compound/receptor complex formation and dissociation.
  • both the “on rate constant” (K on ) and the “off rate constant” (K off ) can be determined by calculation of the concentrations and the actual rates of association and dissociation.
  • the ratio of K off /K on is equal to the dissociation constant K D .
  • K i may be measured by assays such as radioligand binding assays (e.g., procedures as described in Example 4) or similar assays known to those skilled in the art.
  • the relative affinity for each receptor may be determined by a competition binding assay between labeled compounds and increasing concentrations of unlabeled compounds.
  • the binding affinity can be determined by competition FACS using labeled compound or other competitive binding assays.
  • the binding affinity of a compound to a receptor can also be determined by surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • K D or K i may be determined by the BIAcore technology (GE), or the KinExA® (Sapidyne Instruments) affinity analysis.
  • the present invention also provides for a method of treating or preventing conditions described herein by administering to a subject the present compound or composition.
  • Fibrotic diseases include, for example, scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, cystic fibrosis, chronic kidney disease, chronic graft rejection, fibrosis of organs such as liver, esophagus, heart, lung, intestines, etc., and other scarring/wound healing abnormalities, post-operative adhesions, and reactive fibrosis.
  • Fibrotic diseases include, for example, scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, cystic fibrosis, chronic kidney disease, chronic
  • Inflammatory diseases include, for example, systemic lupus erythematosus, AIDs, multiple sclerosis, rheumatoid arthritis, psoriasis, Type 1 diabetes, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, stroke and ischemia.
  • Non-limiting examples of fibrosis include liver fibrosis, lung fibrosis (e.g., silicosis, asbestosis, idiopathic pulmonary fibrosis), oral fibrosis, endomyocardial fibrosis, retroperitoneal fibrosis, deltoid fibrosis, kidney fibrosis (including diabetic nephropathy), cystic fibrosis, and glomerulosclerosis.
  • Liver fibrosis for example, occurs as a part of the wound-healing response to chronic liver injury.
  • Fibrosis can occur as a complication of haemochromatosis, Wilson's disease, alcoholism, schistosomiasis, viral hepatitis, bile duct obstruction, exposure to toxins, and metabolic disorders.
  • Endomyocardial fibrosis is an idiopathic disorder that is characterized by the development of restrictive cardiomyopathy.
  • endomyocardial fibrosis the underlying process produces patchy fibrosis of the endocardial surface of the heart, leading to reduced compliance and, ultimately, restrictive physiology as the endomyocardial surface becomes more generally involved.
  • Oral submucous fibrosis is a chronic, debilitating disease of the oral cavity characterized by inflammation and progressive fibrosis of the submucosal tissues (lamina basement and deeper connective tissues).
  • the buccal mucosa is the most commonly involved site, but any part of the oral cavity can be involved, even the pharynx.
  • Retroperitoneal fibrosis is characterized by the development of extensive fibrosis throughout the retroperitoneum, typically centered over the anterior surface of the fourth and fifth lumbar vertebrae.
  • Scleroderma is a disease of the connective tissue characterized by fibrosis of the skin and internal organs. Scleroderma has a spectrum of manifestations and a variety of therapeutic implications. It comprises localized scleroderma, systemic sclerosis, scleroderma-like disorders, and sine scleroderma. Systemic sclerosis can be diffuse or limited. Limited systemic sclerosis is also called CREST (calcinosis, Raynaud's esophageal dysfunction, sclerodactyly, telangiectasia).
  • Systemic sclerosis comprises: scleroderma lung disease, scleroderma renal crisis, cardiac manifestations, muscular weakness including fatigue or limited CREST, gastrointestinal dysmotility and spasm, and abnormalities in the central, peripheral and autonomic nervous system.
  • the major symptoms or manifestations of scleroderma and in particular of systemic sclerosis are inappropriate excessive collagen synthesis and deposition, endothelial dysfunction, vasospasm, collapse and obliteration of vessels by fibrosis.
  • a compound having the structure as shown in Formula I can be ajulemic acid.
  • applicants have discovered that administration of ultrapure ajulemic acid is effective in treating tissue fibrosis of the lung and skin, as demonstrated using a well-established animal model of scleroderma without any of the CB1-mediated behavioral side effects.
  • a therapeutically effective amount of the present compound may lower the level of pain experienced by a subject.
  • the level of pain experienced by a patient can be assessed by use of a visual analog scale (VAS) or a Likert-type scale.
  • VAS visual analog scale
  • a Likert-type scale is a rating scale, usually in the range of 1 to 5, based on degrees of agreement or disagreement to statements.
  • a similar type of scale although based on an 11 point scale (ranging from 0 to 10) can also be used.
  • Such pain scales can be applied to visualize an alteration of the level of pain a patient experiences during treatment, e.g., a reduction of the level of pain a patient or a population of patients experiences before and after initiation of a pain therapy.
  • U.S. Pat. No. 7,413,748 the pain may be reduced by at least about 1 point, at least about 2 points, at least about 3 points, at least about 4 points, at least about 5 points, at least about 6 points, at least about 7 points, or at least about 8 points on an 11-point pain scale.
  • the level of pain may also be assessed by other suitable methods.
  • a therapeutically effective amount of the present compound may be used to treat or prevent fibrosis.
  • Fibrosis may be assessed using in vitro or in vivo models.
  • in vitro fibrosis can be assayed by measuring the amount of extracellular matrix protein production in response to TGF-beta, PDGF, CTGF, or other pro-fibrotic factors or through the presence of markers of fibroblast activation. Common endpoints include measurement of collagen, fibronectin, and actin.
  • in vivo fibrosis is measured by the degree of extracellular matrix production in a particular tissue.
  • In vivo models of fibrosis include chemically induced models in which an external fibrosis mediator such as bleomycin, HOC1, CC14 or alcohol is used to induce liver, kidney, skin or lung fibrosis.
  • an external fibrosis mediator such as bleomycin, HOC1, CC14 or alcohol
  • Genetic models of fibrosis are also commonly used including animals which overexpress TGF-beta, PDGF, osteopontin and interleukins, plus the tight skin (tsk) mouse model. Fibrosis may also be assessed by other suitable methods.
  • a therapeutically effective amount of the present compound may be used to treat or prevent inflammation.
  • Inflammation may be assessed using in vitro or in vivo models.
  • in vitro inflammation can be assayed by measuring the chemotaxis and activation state of inflammatory cells.
  • inflammation can be measured by examining the production of specific inflammatory mediators such as interleukins, cytokines and eicosanoids mediators.
  • in vivo inflammation is measured by swelling and edema of a localized tissue or migration of leukocytes.
  • Animal models of inflammation may use a stimulus such as phorbol esters, arachidonic acid, platelet activating factor, zymosan, LPS, thioglycollate or other agents to elicit inflammation in tissues such as ear, paw, skin, peritoneum etc.
  • a stimulus such as phorbol esters, arachidonic acid, platelet activating factor, zymosan, LPS, thioglycollate or other agents to elicit inflammation in tissues such as ear, paw, skin, peritoneum etc.
  • Inflammation may also be measured by organ function such as in the lung or kidneys and by the production of pro-inflammatory factors. Inflammation may also be assessed by other suitable methods.
  • the compounds and compositions described herein can be administered to cells in culture, e.g. in vitro or ex vivo, or to a subject, e.g., in vivo, to treat, prevent, and/or diagnose a variety of conditions/diseases as discussed above and further described below.
  • treat or “treatment” includes administration of a compound, e.g., by any route, e.g., orally, to a subject.
  • the compound can be administered alone or in combination with, a second compound. Treatments may be sequential, with the present compound being administered before or after the administration of other agents. Alternatively, agents may be administered concurrently.
  • the subject e.g., a patient, can be one having a disorder (e.g., a disorder as described herein), a symptom of a disorder, or a predisposition toward a disorder.
  • Treatment is not limited to curing or complete healing, but can result in one or more of alleviating, relieving, altering, partially remedying, ameliorating, improving or affecting the disorder, reducing one or more symptoms of the disorder or the predisposition toward the disorder.
  • the treatment (at least partially) alleviates or relieves fibrosis.
  • the treatment reduces at least one symptom of the disorder or delays onset of at least one symptom of the disorder. The effect is beyond what is seen in the absence of treatment.
  • the compound effective to treat a disorder refers to an amount of the compound which is effective, upon single or multiple dose administration to a subject, to achieve treatment.
  • the degree of treatment with a therapeutically effective amount encompasses any improvement or cure of a disease as measured by standard clinically relevant criteria.
  • the amount of a compound effective to prevent a disorder refers to an amount effective, upon single- or multiple-dose administration to the subject, in preventing or delaying the occurrence of the onset or recurrence of a disorder or a symptom of the disorder.
  • Subjects that can be treated with the compounds and methods of the present invention include both human and non-human animals.
  • exemplary human subjects include a human patient having a disorder, e.g., a disorder described herein or a normal subject.
  • the term “non-human animals” of the invention includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dog, cat, cow, pig, etc.
  • the animal is other than a rodent, e.g., a rat or mouse, or a non-human primate.
  • Treatment of subjects can be optimized by titrating the subject, for example, such that treatment can be initiated with sub-optimal or no-effect doses of each compound and increased to determine the optimal dose of ultrapure ajulemic acid for the treatment and/or prevention of fibrotic or inflammatory diseases in the subject.
  • Treating a subject with ultrapure ajulemic acid can cause side effects such as dizziness, dry mouth, headache, nausea, pallor, somnolence, and vomiting.
  • the side effects can be modulated to some extent by starting at a low dose and slowly titrating the dose upward, e.g., during the course of treatment, for example over the course of weeks, months or years.
  • a subject is titrated to minimize the adverse events and achieve a therapeutic level of the appropriate dosage form of ultrapure ajulemic acid.
  • the dosage form is an oral dosage form such as a tablet or capsule or enteric coated tablet or osmotic release capsule or unique combination of excipients.
  • the dosage form is a liquid, topical patch, gel, ointment, cream, aerosol, or inhaled formulation.
  • compositions may be formulated to deliver over a 24-hour period from about 0.5 mg to about 240 mg, from about 5 mg to about 180 mg, or from about 10 mg to about 120 mg of the present ultrapure compound (e.g., ultrapure ajulemic acid).
  • the dosage form includes an additional agent or is provided together with a second dosage form, which includes the additional agent.
  • additional agents include an analgesic agent such as an NSAID or opiate, an anti-inflammatory agent or a natural agent such as a triglyceride containing unsaturated fatty acid, or isolated pure fatty acids such as eicosapentaenoic acid (EPA), dihomogamma linolenic acid (DGLA), docosahexaenoic acid (DHA) and others.
  • the dosage form comprises a capsule wherein the capsule contains a mixture of materials to provide a desired sustained release formulation.
  • the dosage forms can include a tablet coated with a semipermeable coating.
  • the tablet comprises two layers, a layer containing ultrapure ajulemic acid and a second layer referred to as a “push” layer.
  • the semi-permeable coating is used to allow a fluid (e.g., water) to enter the tablet and erode a layer or layers.
  • this sustained release dosage form further comprises a laser hole drilled in the center of the coated tablet.
  • the ajulemic acid or other (3R,4R)- ⁇ 8-tetrahydrocannabinol-11-oic acid containing layer comprises ajulemic acid or another (3R,4R)- ⁇ 8-tetrahydrocannabinol-11-oic acid, a disintegrant, a viscosity enhancing agent, a binding agent and an osmotic agent.
  • the push layer comprises a disintegrant, a binding agent, an osmotic agent and a viscosity enhancing agent.
  • the invention features a dosage form of ultrapure ajulemic acid that is a controlled release dosage form, which provides controlled release of ultrapure ajulemic acid.
  • the dosage form comprises a tablet comprising a biocompatible matrix and ultrapure ajulemic acid.
  • the sustained release dosage form may also comprise a hard-shell capsule containing bio-polymer microspheres that contains the therapeutically active agent.
  • the biocompatible matrix and bio-polymer microspheres each contain pores for drug release and delivery. These pores are formed by mixing the biocompatible matrix of bio-polymer microsphere with a pore forming agent.
  • Each biocompatible matrix or bio-polymer microsphere is made up of a biocompatible polymer or mixture of biocompatible polymers.
  • the matrix and microspheres can be formed by dissolving the biocompatible polymer and active agent (compound described herein) in a solvent and adding a pore-forming agent (e.g., a volatile salt).
  • the sustained release dosage form comprises a tablet, wherein the tablet contains ultrapure ajulemic acid and one or more polymers and wherein the tablet can be prepared by compressing the ultrapure ajulemic acid and one or more polymers.
  • the one or more polymers may comprise a hygroscopic polymer formulated with ultrapure ajulemic acid. Upon exposure to moisture, the tablet dissolves and swells. This swelling allows the sustained release dosage form to remain in the upper GI tract. The swelling rate of the polymer mixture can be varied using different grades of polyethylene oxide.
  • the sustained release dosage form comprises a capsule further comprising particle cores coated with a suspension of active agent and a binding agent which is subsequently coated with a polymer.
  • the polymer may be a rate-controlling polymer. In general, the delivery rate of the rate-controlling polymer is determined by the rate at which the active agent is dissolved.
  • exemplary dosage forms of ultrapure ajulemic acid can be administered to a subject.
  • exemplary dosage forms include oral dosage forms (e.g., a tablet or capsule), topical dosage forms such as a topical patch, gels, and ointments, ophthalmic dosage forms such as drops or liquid formulations, interstitial dosage forms such as liquid formulations, and inhaled dosage forms such as inhalers, nebulizers, aerosols and sprays.
  • the ultrapure ajulemic acid is formulated into a dosage form wherein a single dosage is from about 0.5 mg to about 120 mg once daily or from about 0.15 mg to about 40 mg up to 3 times daily.
  • the ultrapure ajulemic acid is formulated into a dosage form wherein a single dosage is from about 0.01 to about 1.5 mg/kg weight of the subject. In further embodiments, the dosage form is administered up to 3 times daily and from about 0.003 to about 0.5 mg/kg weight of the subject.
  • the term “therapeutically effective amount” is an amount sufficient to treat a specified disorder or disease or alternatively to obtain a pharmacological response treating a disorder or disease.
  • Methods of determining the most effective means and dosage of administration can vary with the composition used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Treatment dosages generally may be titrated to optimize safety and efficacy. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. Suitable dosage formulations and methods of administering the agents can be readily determined by those of skill in the art.
  • the composition may be administered at about 0.01 mg/kg to about 200 mg/kg, about 0.1 mg/kg to about 100 mg/kg, or about 0.5 mg/kg to about 50 mg/kg.
  • the effective amount may be less than when the agent is used alone.
  • one or more of the therapeutic agents that can be used in the methods of the present invention for preventing and/or treating conditions discussed above are formulated with a pharmaceutically acceptable carrier, vehicle or adjuvant.
  • pharmaceutically acceptable carrier, vehicle or adjuvant refers to a carrier, vehicle or adjuvant that may be administered to a subject, together with the present compounds, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • the compound may be formulated as a salt such as a pharmaceutically acceptable salt form, which includes, but are not limited to, acid addition salts formed with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as, but not limited to, acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic, acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and polygalacturonic acid.
  • inorganic acids e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like
  • organic acids such as, but not limited to, acetic acid, oxalic acid
  • Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases.
  • Suitable pharmaceutically-acceptable base addition salts include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the dosage forms of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-E-tocopherol polyethylene-glycol 1000 succinate; surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices; serum proteins such as human serum albumin; buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts; or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxmethylcellulose, polyacrylates, waxes, polyethylene-
  • Cyclodextrins such as alpha, beta and ⁇ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-beta cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein that can be used in the methods of the present invention for preventing and/or treating fibrotic conditions. Additional suitable excipients may be found in Handbook of Pharmaceutical Excipients, R. C. Rowe, et. al., Pharmaceutical Press, 2009 [9].
  • unit dosage formulations are compounded for immediate release, though unit dosage formulations compounded for delayed or prolonged release of one or both agents are also disclosed.
  • the therapeutic agents that can be used in the present methods are formulated in a single unit dose such that the agents are released from the dosage at different times.
  • the agent is formulated to provide extended release.
  • the agent is formulated with an enteric coating.
  • the agent is formulated using a biphasic controlled release delivery system, thereby providing prolonged gastric residence.
  • the delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophobic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules.
  • the agent is incorporated into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode.
  • the ultrapure ajulemic acid in the formulation may be formulated as a combination of fast-acting and controlled release forms.
  • the ultrapure ajulemic acid is formulated with a single release property.
  • it is not present in a modified release form, e.g., a controlled release form.
  • compositions may be taken just prior to or with each of three meals, each of two major meals, or one meal.
  • a composition disclosed herein can be administered once a day or twice a day and need not be administered just before or with a meal.
  • the dosage forms of this invention that can be used in the present methods may be administered orally, parentally, by inhalation spray, topically, rectally, interstitially, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection.
  • the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the dosage forms that can be used in the present methods may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions.
  • surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • the present compounds or compositions may be administered orally, for example as a component in a dosage form.
  • the dosage forms may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • the dosage forms of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
  • carriers that are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
  • compositions can be prepared by mixing a compound of this invention that can be used in the methods of the present invention for preventing and/or treating fibrotic conditions with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • Ophthalmic administration of the dosage forms of this invention is useful when the desired treatment involves areas or organs readily accessible by ophthalmic application.
  • the composition could be applied by instillation of a cream, an ointment, or a liquid drop preparation in the conjunctival sac.
  • Topical administration of the dosage forms of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the dosage form For application topically to the skin, the dosage form should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical composition that can be used in the methods of the present invention can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
  • compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
  • the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
  • the dosage form that can be used in the methods of the present invention comprises a capsule wherein the capsule comprises a mixture of material to provide the desired sustained release.
  • the dosage form that can be used in the methods of the present invention comprises a tablet coated with a semipermeable coating.
  • the tablet comprises two layers, a layer containing ultrapure ajulemic acid and a second layer referred to as a “push” layer.
  • the semi-permeable coating is used to allow a fluid (e.g., water) to enter the tablet and erode a layer or layers.
  • the sustained release dosage form further comprises a laser hole drilled in the center of the coated tablet.
  • the ultrapure ajulemic acid containing layer comprises ultrapure ajulemic acid, a disintegrant, a viscosity enhancing agent, a binding agent and an osmotic agent.
  • the push layer comprises a disintegrant, a binding agent, an osmotic agent and a viscosity-enhancing agent.
  • the dosage form that can be used in the methods of the present invention comprises a tablet comprising a biocompatible matrix and an ultrapure ajulemic acid.
  • the sustained release dosage form may also comprise a hard-shell capsule containing bio-polymer microspheres that contains the therapeutically active agent.
  • the biocompatible matrix and bio-polymer microspheres each contain pores for drug release and delivery. These pores are formed by mixing the biocompatible matrix or bio-polymer microsphere with a pore forming agent.
  • Each biocompatible matrix of bio-polymer microsphere is made up of a biocompatible polymer or mixture of biocompatible polymers.
  • the matrix and microspheres can be formed by dissolving the biocompatible polymer and active agent (compound described herein) in a solvent and adding a pore forming agent (e.g., a volatile salt). Evaporation of the solvent and pore forming agent provides a matrix or microsphere containing the active compound.
  • a pore forming agent e.g., a volatile salt
  • the one or more polymers may comprise a hygroscopic polymer formulated with the ultrapure ajulemic acid active agent (i.e., a compound described herein).
  • the tablet dissolves and swells. This swelling allows the sustained release dosage form to remain in the upper GI tract.
  • the swelling rate of the polymer mixture can be varied using different grades of polyethylene oxide.
  • the sustained release dosage form that can be used in the methods of the present invention comprises a capsule further comprising particle cores coated with a suspension of active agent and a binding agent which is subsequently coated with a polymer.
  • the polymer may be a rate-controlling polymer. In general, the delivery rate of the rate-controlling polymer is determined by the rate at which the active agent is dissolved.
  • Non-limiting examples of capsules include but are not limited to gelatin capsules, HPMC, hard shell, soft shell, or any other suitable capsule for holding a sustained release mixture.
  • the solvents used in the above sustained release dosage forms include, but are not limited to ethyl acetate, triacetin, dimethyl sulfoxide (DIV1S0), propylene carbonate, N-methylpyrrolidone (NMP), ethyl alcohol, benzyl alcohol, glycofurol, alpha-tocopherol, Miglyol 810, isopropyl alcohol, diethyl phthalate, polyethylene glycol 400 (PEG 400), triethyl citrate, and benzyl benzoate.
  • DIV1S0 dimethyl sulfoxide
  • NMP N-methylpyrrolidone
  • ethyl alcohol benzyl alcohol
  • glycofurol alpha-tocopherol
  • Miglyol 810 isopropyl alcohol, diethyl
  • the viscosity modifiers used in the above sustained release dosage forms include, but are not limited to caprylic/capric triglyceride (Migliol 810), isopropyl myristate (IPM), ethyl oleate, triethyl citrate, dimethyl phthalate, benzyl benzoate and various grades of polyethylene oxide.
  • the high viscosity liquid carrier used in the above sustained release dosage forms include, but are not limited to sucrose acetate isobutyrate (SA1B) and cellulose acetate butyrate (CAB) 381-20.
  • Non-limiting examples of materials that make up preferred semi-permeable layers include, but are not limited to cellulosic polymers such as cellulose acetate, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose diacetate, cellulose triacetate or any mixtures thereof; ethylene vinyl acetate copolymers, polyethylene, copolymers of ethylene, polyolefins including ethylene oxide copolymers (e.g., Engage®—Dupont Dow Elastomers), polyamides, cellulosic materials, polyurethanes, polyether blocked amides, and copolymers (e.g., PEBAX®, cellulosic acetate butyrate and polyvinyl acetate).
  • Non-limiting examples of disintegrants that may be employed in the above sustained release dosage forms include but are not limited to croscarmellose sodium, crospovidone, sodium alginate or similar excipients.
  • Non-limiting examples of binding agents that may be employed in the above sustained release dosage forms include but are not limited to hydroxyalkylcellulose, a hydroxyalkylalkylcellulose, or a polyvinylpyrrolidone.
  • Non-limiting examples of osmotic agents that may be employed in the above sustained release dosage forms include but are not limited to, sorbitol, mannitol, sodium chloride, or other salts.
  • biocompatible polymers employed in the above sustained release dosage forms include but are not limited to poly(hydroxyl acids), polyanhydrides, polyorthoesters, polyamides, polycarbonates, polyelkylenes, polyelkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polysiloxanes, poly(vinyl alcohols), poly (vinyl acetate), polystyrene, polyurethanes and co-polymers thereof, synthetic celluloses, polyacrylic acids, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone),
  • Non-limiting examples of hygroscopic polymers that may be employed in the above sustained release dosage forms include but are not limited to polyethylene oxide (e.g., Polyox® with MWs from 4,000,000 to 10,000,000), cellulose hydroxymethyl cellulose, hydroxyethyl-cellulose, crosslinked polyacrylic acids and xanthum gum.
  • polyethylene oxide e.g., Polyox® with MWs from 4,000,000 to 10,000,000
  • cellulose hydroxymethyl cellulose hydroxyethyl-cellulose
  • crosslinked polyacrylic acids xanthum gum.
  • Non-limiting examples of rate-controlling polymers the may be employed in the above sustained release dosage forms includes but is not limited to polymeric acrylate, methacrylatelacquer or mixtures thereof, polymeric acrylate lacquer, methacrylate lacquer, an acrylic resin comprising a copolymer of acrylic and methacrylic acid esters or an ammonium methacrylate lacquer with a plasticizer.
  • a dosage form described herein may be provided in a kit.
  • the kit includes (a) a compound used in a method described herein, and, optionally (b) informational material.
  • the informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of the dosage form for the methods described herein.
  • the informational material of the kits is not limited in its form.
  • the informational material can include information about production of the compound, molecular weight of the compound, concentration, date of expiration, batch or production site information, and so forth.
  • the informational material relates to methods for administering the compound.
  • the informational material can include instructions to use a compound described herein in a suitable manner to perform the methods described herein, e.g., carry out a reaction to produce a compound described herein.
  • the informational material of the kits is not limited in its form.
  • the informational material e.g., instructions
  • the informational material is provided in printed matter, e.g., a printed text, drawing, and/or photograph, e.g., a label or printed sheet.
  • the informational material can also be provided in other formats, such as Braille, computer readable material, video recording, or audio recording.
  • the informational material of the kit is contact information, e.g., a physical address, email address, website, or telephone number, where a user of the kit can obtain substantive information about a compound described herein and/or its use in the methods described herein.
  • the informational material can also be provided in any combination of formats.
  • the composition of the kit can include other ingredients, such as a solvent or buffer, a stabilizer, a preservative, a flavoring agent (e.g., a bitter antagonist or a sweetener), a fragrance, a dye or coloring agent, for example, to tint or color one or more components in the kit, or other cosmetic ingredient, and/or a second agent for treating a condition or disorder described herein.
  • the other ingredients can be included in the kit, but in different compositions or containers than a compound described herein.
  • the kit can include instructions for admixing a compound described herein and the other ingredients, or for using a compound described herein together with the other ingredients.
  • the components of the kit are stored under inert conditions (e.g., under Nitrogen or another inert gas such as Argon). In some embodiments, the components of the kit are stored under anhydrous conditions (e.g., with a desiccant). In some embodiments, the components are stored in a light blocking container such as an amber vial.
  • inert conditions e.g., under Nitrogen or another inert gas such as Argon.
  • anhydrous conditions e.g., with a desiccant
  • the components are stored in a light blocking container such as an amber vial.
  • a dosage form described herein can be provided in any form, e.g., liquid, dried or lyophilized form. It is preferred that a compound described herein be substantially pure and/or sterile.
  • the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being preferred.
  • reconstitution generally is by the addition of a suitable solvent.
  • the solvent e.g., sterile water or buffer, can optionally be provided in the kit.
  • the kit can include one or more containers for the composition containing a dosage form described herein.
  • the kit contains separate containers, dividers or compartments for the composition and informational material.
  • the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained in a plastic sleeve or packet.
  • the separate elements of the kit are contained within a single, undivided container.
  • the dosage form is contained in a bottle, vial or syringe that has attached thereto the informational material in the form of a label.
  • the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of a compound described herein.
  • the kit includes a plurality of syringes, ampules, foil packets, or blister packs, each containing a single unit dose of a dosage form described herein.
  • the containers of the kits can be air tight, waterproof (e.g., impermeable to changes in moisture or evaporation), and/or light-tight.
  • the kit optionally includes a device suitable for use of the dosage form, e.g., a syringe, pipette, forceps, measured spoon, swab (e.g., a cotton swab or wooden swab), or any such device.
  • a device suitable for use of the dosage form e.g., a syringe, pipette, forceps, measured spoon, swab (e.g., a cotton swab or wooden swab), or any such device.
  • Ultrapure ajulemic acid JBT-101 was synthesized and its binding to CB1 and CB2 receptors was compared to that of previous preparations.
  • the binding affinity of ultrapure AJA for CB2 is about 10 ⁇ to 20 ⁇ greater than the binding affinity for CB1.
  • FIG. 9 shows various other K i and K i (CB1)/K i (CB2) ratios for various other cannabinoids and other previous synthetically produced AJA [10, 11].
  • JBT-101 was assessed for its ability to stimulate[35S]GTP ⁇ S turnover in CB1 and CB2 receptors in vitro.
  • the compound was also assessed for its antinociceptive effects in a hot plate assay and for cataleptic effects in a ring immobility test, both in female CD-1 mice. Rectal temperature was also measured in these mice.
  • the hot-plate test was used to measure the analgesic activity of ultrapure AJA and other pharmacologic agents based on the reaction time of mice to lick their forepaws and/or jump after being placed on an aluminum hot plate heated to, and maintained at, 54° C.-56° C. Kitchen I and Green P G, Differential Effects of DFP Poisoning and Its Treatment on Opioid Antinociception in the Mouse, Life Sci. 33:669-672 (1983). This test has been shown to measure CB1 agonist activity.
  • a dose response was conducted for ultrapure AJA at doses from 0.05 to 56 mg/kg.
  • the ultrapure AJA required much higher doses than the AJA from U.S. Pat. No. 5,338,753 to see analgesia.
  • the cataleptic response was measured using the ring test described by Pertwee (Pertwee RG, The Ring Test. A Quantitative Method of Assessing the Cataleptic Effect of Cannabis in Mice, Br. J. Pharmacol. 46:753-763 (1972)). Mice were placed on a horizontal wire ring 5.5 cm in diameter attached to a 16 cm vertical rod. The hind paws and fore paws were placed at opposite sides of the ring. The ambient temperature was maintained at 30° C. and the environment was free of auditory stimuli and bright lights. The response was calculated as the fraction of time the mouse was immobile over a five (5) minute test period. A dose response was conducted for ultrapure AJA to oral doses of 0.05 to 56 mg/kg.
  • the ultrapure AJA required much higher doses then the AJA (3a) from the U.S. Pat. No. 5,338,753 to see catalepsy.
  • a GTP-gamma-S assay was used to study the functional activity of AJA on human CB1 and CB2 receptors to further determine the selectivity of ultrapure AJA for the CB2 receptor. As shown in FIG. 13 , the potency of ultrapure AJA in the GTP-gamma-S assay was ⁇ 10 ⁇ better in the CB2 assay than in the CB1 assay which further supporting the improved selectivity of ultrapure AJA for CB2 vs CB1.
  • the JBT-101 stock solution was prepared in ethanol or DMSO.
  • ⁇ 9 -THC National Institute on Drug Abuse (NIDA), Rockville, Md.], indomethacin (Sigma-Aldrich, St. Louis, Mo.), and JBT-101 were dissolved in a vehicle of peanut or safflower oil (food grade). Compounds were administered at a volume of 20 ⁇ l/kg via oral gavage.
  • the CB1 and CB2 receptor assays involve membrane preparations purchased from Perkin Elmer (Waltham, Mass.) isolated from a HEK-293 expression system.
  • G-protein coupled signal transduction (GTP- ⁇ -[35S]) assays of test compounds were conducted in an incubation mixture consisting of a test compound (250 nM-1 mM), GDP (20 ⁇ M), GTP- ⁇ -[35S] (100 pM), and the hCB1 and hCB2 membrane preparations (0.4 pM) in a total volume of 0.4 mL of assay buffer (50 mM TRIS-HCl, pH 7.4, 1 mM EDTA, 100 mM NaCl, 5 mM MgCl2, 0.5% (w/v) BSA).
  • Nonspecific binding was determined in the presence of 100 ⁇ M unlabeled GTP- ⁇ -S, and basal binding was determined in the absence of drug. Duplicate samples were incubated for 1 h at 30° C., and the bound complex was filtered from the reaction mixture as described previously and counted in a liquid scintillation counter. Specific binding was calculated by subtracting nonspecific binding from total binding and dividing by the total basal binding minus nonspecific binding. Data were plotted and analyzed with GraphPad Prism (GraphPad Software, Inc., San Diego, Calif.).
  • the EC50 for JBT-101 at the CB1 receptor was 9209 ⁇ 2042 nM whereas the EC50 at the CB2 receptor was 1020 ⁇ 92 nM (Table 2).
  • the 9-fold difference in potency for activation of CB2 versus CB1 receptors is consistent with the 12-fold selectivity of this compound for binding CB2 receptors, suggesting that JBT-101 would activate CB2 receptors at doses that are not active at CB1 receptors.
  • mice Female CD-1 mice (20-25 g), obtained from Charles River (Raleigh, N.C.), were used for assessment in hot plate nociception, rectal temperature, and ring immobility assays. Separate mice were used for testing each dose of each compound in this battery of procedures. The mice had free access to food and water when in their home cages. All animals were kept in a temperature-controlled (20-22° C.) environment with a 12-hour light-dark cycle (lights on at 7 a.m.).
  • mice were tested in a battery of three tests, in which cannabinoid CB1 agonists produce in vivo effects in mice (Martin et al., 1991): antinociception (hot plate assay), decreased rectal temperature and ring immobility. Prior to administration of the test compound, rectal temperature and baseline latency in the hot plate test were measured in the mice. The latter procedure involved placing the mouse on a heated surface (mouse cold/hot plate analgesia apparatus; Stoelting, Wood Dale, Ill.) at a setting of 55° C. Time until the mouse lifts or licks a paw was measured, whereupon the mouse was removed from the apparatus.
  • a heated surface mouse cold/hot plate analgesia apparatus
  • mice were administered vehicle or drug via oral gavage. Hot plate latency and temperature were measured again at 90 minutes after administration (via oral gavage) of peanut oil vehicle or JBT-101 or at 60 minutes after administration (via oral gavage) of ⁇ 9-THC or indomethacin. Subsequently, the mice were placed on a 5.5 cm ring attached at a height of 16 cm to a ring stand, and the amount of time the animals remained motionless during a 5 min period was recorded. In addition, the number of times the mouse fell or jumped off the ring was recorded. If the mouse fell off the ring more than 5 times, the test was terminated.
  • Rectal temperature values were expressed as the difference between control temperature (before injection) and temperature following drug administration (4° C.). Antinociception was expressed as the percent maximum possible effect (MPE) using a 30-s maximum test latency as follows: [(test-control)/(30-control)] ⁇ 100.
  • MPE percent maximum possible effect
  • JBT-101 increased ring immobility at higher doses (30 and 56 mg/kg), with a magnitude similar to that produced by 30 mg/kg ⁇ 9-THC, its overall pattern of pharmacological effects did not suggest ⁇ 9-THC-like psychoactivity.
  • Previously synthesized (non-purified) ajulemic acid has shown efficacy in several preclinical models of pain and inflammation (reviewed in Wiley, 2005); however, it also produced a profile of pharmacological effects in vivo that is characteristic of ⁇ 9-THC and other psychoactive CB1 receptor agonists. These effects included suppression of spontaneous activity, antinociception, hypothermia, and catalepsy in mice and ⁇ 9-THC-like discriminative stimulus effects in rats (Vann et al., 2007).
  • JBT-101 increased ring immobility, it did so only at higher doses (30 and 56 mg/kg). Together, these results demonstrate that the effects of JBT-101 differ from those of earlier syntheses of (non-purified) ajulemic acid. In conclusion, the pharmacological profile of JBT-101 is consistent with it being a CB2 selective compound with little CB1 receptor activity.
  • FIG. 12 shows the binding curves for ultrapure AJA and reference cannabinoid antagonists selective for CB2 and CB1.
  • Membrane preparation HEK-293T cells were cultured according to ATCC (Manassas, Va.) guidelines and transfected with human CB1 cDNA (Genbank X54937) or CB2 cDNA (Genbank X74328), operably linked to the SV40 promoter, using Polyfect (Qiagen, Valencia, Calif.) or Fugene (Roche, Nutley, N.J.) according to manufacturer's instructions. 48 h after transfection, cells were harvested in ice cold membrane buffer (20 mM HEPES, 6 mM MgCl2, 1 mM EDTA, pH 7.2) using a cell scraper. Cells were transferred to a nitrogen cavitation chamber and a pressure of 900 bar was applied for 30 min.
  • Binding assay 0.5-10 ng of membranes expressing human CB1 or human CB2 receptors were incubated in binding buffer (50 mM Tris, 10 mM MgCl2, 1 mM EDTA, 0.1% BSA, pH 7.4) in the presence of 0.5 to 2 nM radioligand ([3H]-CP55940; Perkin Elmer except 3 nM [3H]-SR141716 was used as the radioligand where noted), and varying concentrations of ligands (total volume 200 ⁇ L/well of a 96 well plate).
  • Membranes were incubated for 2 hr at room temperature, then filtered onto a presoaked (with 0.1% polyethylenimine for 1 to 2 hr) 96 well GF/B filterplate (Packard Bioscience, Shelton, Conn.) and washed with 500 mL ice cold wash buffer (25 mM HEPES, 1 mM CaCl 2 , 5 mM MgCl2, 0.25M NaCl) using a Filtermate 196 Harvester (Packard Instruments, Downers Grove, Ill.). The filter plates were dried before addition of 50 ⁇ L of scintillation fluid to each well (Microscint 20, Packard, Shelton, Conn.). Plates were counted on a Topcount NXT (Packard, Shelton, Conn.).
  • Ki values were calculated from IC 50 values using the Cheng & Prussoff method using reported Ki values of 2.9 nM for SR141716 receptors for human CB1 receptors, and 2.5 nM and 0.92 nM for CP55,940 for human CB1 and human CB2 receptors, respectively (McPartland et al, BJP, 2007).
  • mice received daily s.c. injections of bleomycin (20 ug/mouse) or vehicle for 14 days, followed by one weeks of recovery.
  • bleomycin (20 ug/mouse) or vehicle for 14 days, followed by one weeks of recovery.
  • MC 2% methylcellulose
  • mice were sacrificed. Their skin was harvested and processed for routine histology (H&E, trichrome and picrosirius red stains), immunohistology (paraffin-embedded or frozen samples), in situ hybridization, collagen (SIRCOL) assays, and RNA isolation for real-time qPCR or microarray hybridization. Skin sections were carefully characterized and quantified for dermal inflammation, dermal thickening, collagen accumulation (Trichrome), and collagen cross-linking (Sirius red) in lesional skin.
  • CD-1 Mice Male were randomly allocated to experimental groups and allowed to acclimatise for one week. Prior to test compound administration, baseline right hind paw volume was measured under gas (isoflurane) anaesthesia using a water displacement device (plethysmometer, Stoelting). On Day 0, ultrapure AJA suspended in 2% MC or vehicle was administered at 0, 5, 50 and 500 ug/kg by oral gavage. Ninety minutes after treatment administration, the animals were given 10 microliters of a 100 mg/ml arachidonic acid solution in 5% ethanol by subcutaneous injection into the plantar aspect of the right hind paw. A control group of animals (Group 1) was administered with an equivalent volume of a 5% ethanol solution. The left hind paws were not injected. Intra-plantar injections were performed under gas anaesthesia. 45 minutes after the intra-plantar injections right hind paw volume was measured under gas anaesthesia using a plethysmometer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
US14/546,116 2013-02-12 2014-11-18 Ultrapure tetrahydrocannabinol-11-oic acids Abandoned US20150141501A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/546,116 US20150141501A1 (en) 2013-02-12 2014-11-18 Ultrapure tetrahydrocannabinol-11-oic acids
US15/220,127 US10085964B2 (en) 2013-02-12 2016-07-26 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,059 US9801849B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,104 US9820964B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/698,544 US10154986B2 (en) 2013-02-12 2017-09-07 Ultrapure tetrahydrocannabinol-11-oic acids
US16/198,381 US10369131B2 (en) 2013-02-12 2018-11-21 Ultrapure tetrahydrocannabinol-11-oic acids
US16/425,196 US11052066B2 (en) 2013-02-12 2019-05-29 Ultrapure tetrahydrocannabinol-11-oic acids
US17/336,759 US20220117931A1 (en) 2013-02-12 2021-06-02 Ultrapure tetrahydrocannabinol-11-oic acids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US201361837743P 2013-06-21 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids
US14/546,116 US20150141501A1 (en) 2013-02-12 2014-11-18 Ultrapure tetrahydrocannabinol-11-oic acids

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2014/016050 Continuation WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids
US15/220,127 Continuation US10085964B2 (en) 2013-02-12 2016-07-26 Ultrapure tetrahydrocannabinol-11-oic acids
US15/698,544 Continuation US10154986B2 (en) 2013-02-12 2017-09-07 Ultrapure tetrahydrocannabinol-11-oic acids

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/220,127 Continuation US10085964B2 (en) 2013-02-12 2016-07-26 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,104 Division US9820964B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,059 Division US9801849B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids

Publications (1)

Publication Number Publication Date
US20150141501A1 true US20150141501A1 (en) 2015-05-21

Family

ID=51354671

Family Applications (8)

Application Number Title Priority Date Filing Date
US14/546,116 Abandoned US20150141501A1 (en) 2013-02-12 2014-11-18 Ultrapure tetrahydrocannabinol-11-oic acids
US15/220,127 Active US10085964B2 (en) 2013-02-12 2016-07-26 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,104 Active US9820964B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,059 Expired - Fee Related US9801849B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/698,544 Active US10154986B2 (en) 2013-02-12 2017-09-07 Ultrapure tetrahydrocannabinol-11-oic acids
US16/198,381 Active US10369131B2 (en) 2013-02-12 2018-11-21 Ultrapure tetrahydrocannabinol-11-oic acids
US16/425,196 Expired - Fee Related US11052066B2 (en) 2013-02-12 2019-05-29 Ultrapure tetrahydrocannabinol-11-oic acids
US17/336,759 Abandoned US20220117931A1 (en) 2013-02-12 2021-06-02 Ultrapure tetrahydrocannabinol-11-oic acids

Family Applications After (7)

Application Number Title Priority Date Filing Date
US15/220,127 Active US10085964B2 (en) 2013-02-12 2016-07-26 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,104 Active US9820964B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/347,059 Expired - Fee Related US9801849B2 (en) 2013-02-12 2016-11-09 Ultrapure tetrahydrocannabinol-11-oic acids
US15/698,544 Active US10154986B2 (en) 2013-02-12 2017-09-07 Ultrapure tetrahydrocannabinol-11-oic acids
US16/198,381 Active US10369131B2 (en) 2013-02-12 2018-11-21 Ultrapure tetrahydrocannabinol-11-oic acids
US16/425,196 Expired - Fee Related US11052066B2 (en) 2013-02-12 2019-05-29 Ultrapure tetrahydrocannabinol-11-oic acids
US17/336,759 Abandoned US20220117931A1 (en) 2013-02-12 2021-06-02 Ultrapure tetrahydrocannabinol-11-oic acids

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP2956133A4 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN105228613A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801849B2 (en) 2013-02-12 2017-10-31 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190133995A1 (en) * 2016-04-29 2019-05-09 Corbus Pharmaceuticals, Inc. Methods for the treatment of infection
EP3481371A1 (en) * 2016-07-11 2019-05-15 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
US20220023253A1 (en) * 2020-07-21 2022-01-27 Np Pharma Holdings, Llc Cannabinoid Compositions and Methods for Treating Joint Pain and Inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060636A1 (en) * 2002-12-04 2007-03-15 Haim Aviv High enantiomeric purity dexanabinol for pharmaceutical compositions
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7399872B2 (en) * 2001-03-07 2008-07-15 Webster G R Barrie Conversion of CBD to Δ8-THC and Δ9-THC
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
US7413748B2 (en) 2002-12-13 2008-08-19 Purdue Pharma L.P. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004058251A1 (en) 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
AU2006240490A1 (en) 2005-04-21 2006-11-02 Paladin Labs (Barbados) Inc. Process for the preparation of ultrapure 4-methylprazole
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
DK1903866T3 (en) 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
US9192598B2 (en) 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
US20130338220A1 (en) 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060636A1 (en) * 2002-12-04 2007-03-15 Haim Aviv High enantiomeric purity dexanabinol for pharmaceutical compositions
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Batista, C., "Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry." Journal of Chromatography B 820.1 (2005): 77-82. *
Brownjohn, P. W.,"Cannabinoids and neuropathic pain." Neuropathic Pain (2012): 79-102. *
Burstein, S.H.,"Ajulemic acid: a novel cannabinoid produces analgesia without a “high”." Life sciences 75.12 (2004): 1513-1522. *
Flörke, O.W. "Silica." Ullmann's Encyclopedia of Industrial Chemistry (2008). *
Hill, M.N.,"Enhancement of anxiety-like responsiveness to the cannabinoid CB 1 receptor agonist HU-210 following chronic stress." European journal of pharmacology 499.3 (2004): 291-295. *
Jones, R.T.,"Clinical studies of cannabis tolerance and dependence." Annals of the New York Academy of Sciences 282.1 (1976): 221-239. *
Mullin, J.W., "Crystallization and precipitation." Ullmann's Encyclopedia of Industrial Chemistry (2002): 582-630. *
Shekunov, B., "Crystallization processes in pharmaceutical technology and drug delivery design." Journal of crystal growth 211.1 (2000): 122-136. *
Tepper, M.A., "Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity." Bioorganic & medicinal chemistry 22.13 (2014): 3245-3251. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801849B2 (en) 2013-02-12 2017-10-31 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
US9820964B2 (en) 2013-02-12 2017-11-21 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
US10085964B2 (en) 2013-02-12 2018-10-02 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
US10154986B2 (en) 2013-02-12 2018-12-18 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
US10369131B2 (en) 2013-02-12 2019-08-06 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
US11052066B2 (en) 2013-02-12 2021-07-06 Corbus Pharmaceuticals, Inc. Ultrapure tetrahydrocannabinol-11-oic acids
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
WO2021072325A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof

Also Published As

Publication number Publication date
JP6689078B2 (ja) 2020-04-28
CN105228613A (zh) 2016-01-06
JP2021185166A (ja) 2021-12-09
US9820964B2 (en) 2017-11-21
EP2956133A4 (en) 2016-12-21
US9801849B2 (en) 2017-10-31
KR20190139327A (ko) 2019-12-17
US10369131B2 (en) 2019-08-06
US10154986B2 (en) 2018-12-18
AU2014216440B2 (en) 2018-08-09
AU2018258159B2 (en) 2020-01-02
WO2014127016A2 (en) 2014-08-21
AU2014216440A1 (en) 2015-08-20
CN110946854A (zh) 2020-04-03
AU2018258159A1 (en) 2018-11-22
KR20160002709A (ko) 2016-01-08
US20170071900A1 (en) 2017-03-16
US20180177757A1 (en) 2018-06-28
US20170071899A1 (en) 2017-03-16
CA2900982A1 (en) 2014-08-21
US20220117931A1 (en) 2022-04-21
JP2016510340A (ja) 2016-04-07
EP3851101A1 (en) 2021-07-21
BR112015019180A8 (pt) 2018-01-30
CA2900982C (en) 2021-06-01
JP2019031505A (ja) 2019-02-28
EP2956133A2 (en) 2015-12-23
US20190091200A1 (en) 2019-03-28
US11052066B2 (en) 2021-07-06
US20200093784A1 (en) 2020-03-26
US10085964B2 (en) 2018-10-02
WO2014127016A3 (en) 2015-11-26
US20170071898A1 (en) 2017-03-16
BR112015019180A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
US11052066B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
TW200825094A (en) Therapeutic pyrazolyl thienopyridines
US20210198223A1 (en) Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol
US10329243B2 (en) Biphenyl derivative and uses thereof
US12435037B2 (en) Acetylsalicylic acid derivative and application thereof
US20180185299A1 (en) The use of diphenol in preparation of medicines for prevention and treatment of cerebral ischemia
WO2022256540A1 (en) Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
KR20120025440A (ko) 세스터터핀 화합물 및 이들 물질의 용도
HK40026965A (en) Ultrapure tetrahydrocannabinol-11-oic acids
CN100475804C (zh) 一类异色满酮-4衍生物、其制备方法及其医疗用途
WO2006007794A1 (en) Cis-1,2-substituted stilbene derivates and the use thererof for manufacturing medicaments for treating medicaments for treating and/or preventing diabetes
CN104873482B (zh) 一种抗慢性心力衰竭的药物组合物
US9745275B2 (en) Pain-related compound and medical composition
JP2025533120A (ja) イミダゾリジニルバニリン酸エーテル誘導体の線維化を伴う疾患の治療における使用
US20200179302A1 (en) Use of diphenol in preparation of medicines for prevention and treatment of cerebral ischemia

Legal Events

Date Code Title Description
AS Assignment

Owner name: CORBUS PHARMACEUTICS INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEPPER, MARK;REEL/FRAME:034201/0782

Effective date: 20141117

AS Assignment

Owner name: CORBUS PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEPPER, MARK;REEL/FRAME:042059/0088

Effective date: 20170414

AS Assignment

Owner name: CORBUS PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEPPER, MARK;REEL/FRAME:042133/0908

Effective date: 20170420

Owner name: CORBUS PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEPPER, MARK;REEL/FRAME:042133/0881

Effective date: 20170420

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION